RNS XF-73 Significant Potential5 Aug 2024 09:49
Just a shame on the funding side that no investor has stepped up yet, but drug is surely going to be a winner in Phase 3…these results surely will generate hugh interest:
Dr Bill Love, Chief Scientific Officer Destiny Pharma, said: "These results from an in vivo burn wound infection model provide clear evidence that XF-73 can significantly reduce the risk, or even eliminate MRSA from reaching the bloodstream and causing sepsis. It is seen as a significant result for the continued development of our XF-73 dermal product."